Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tarsus Pharmaceuticals Inc TARS

Healthcare
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API... see more

Recent & Breaking News (NDAQ:TARS)

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

GlobeNewswire August 1, 2023

Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock

GlobeNewswire July 31, 2023

FDA Approves XDEMVY(TM) (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis

GlobeNewswire July 25, 2023

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

GlobeNewswire June 12, 2023

Tarsus to Present at the Jefferies Global Healthcare Conference

GlobeNewswire June 5, 2023

Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements

GlobeNewswire May 9, 2023

Tarsus Launches "Don't Freak Out. Get Checked Out." Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

GlobeNewswire May 8, 2023

Tarsus to Participate at the Bank of America 2023 Healthcare Conference

GlobeNewswire May 3, 2023

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

GlobeNewswire April 24, 2023

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

GlobeNewswire March 13, 2023

Tarsus to Present at Upcoming Investor Conferences

GlobeNewswire March 2, 2023

Tarsus Added to NASDAQ Biotechnology Index

GlobeNewswire December 16, 2022

Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease

GlobeNewswire December 15, 2022

Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements

GlobeNewswire November 9, 2022

Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting

GlobeNewswire October 25, 2022

Tarsus Announces Transition Plans for Board of Directors

GlobeNewswire October 11, 2022

Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair

GlobeNewswire October 6, 2022

Tarsus Launches "Look at the Lids" Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis

GlobeNewswire September 29, 2022

Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings

GlobeNewswire September 27, 2022

Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis

GlobeNewswire September 7, 2022